Glomerular binding of anti-dsDNA autoantibodies: The dispute resolved?  by van Bavel, C.C. et al.
600   Kidney International (2007) 71
commentar y
see original article on page 664
http://www.kidney-international.org
© 2007 International Society of Nephrology
Glomerular binding of anti-dsDNA 
autoantibodies: The dispute 
resolved?
CC van Bavel1,2, J van der Vlag1,2 and JH Berden1,2
The binding of anti-double-stranded DNA (anti-dsDNA) autoantibodies 
to the glomerular basement membrane (GBM) in lupus nephritis can be 
explained by two mechanisms: (1) direct crossreactive binding to intrinsic 
glomerular antigens; (2) nucleosome-mediated binding to heparan 
sulfate in the GBM. Kalaaji et al. demonstrated using novel techniques that 
glomerular in vivo-bound antoantibodies bind to nucleosomes/dsDNA 
derived from apoptotic cells and not to intrinsic glomerular structures.
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Background
In general, lupus nephritis is associated 
with high titers of circulating high-affi  n-
ity, IgG anti-double-stranded DNA 
(anti-dsDNA) antibodies and glomerular 
immunoglobulin deposits. Furthermore, 
elution of immunoglobulin from glomer-
uli revealed enrichment for anti-dsDNA 
antibodies. Th erefore, it has been postu-
lated that anti-dsDNA autoantibodies are 
nephritogenic in lupus nephritis. Later it 
became clear that not dsDNA itself but the 
nucleosome is the major driving autoan-
tigen leading to the formation of nucleo-
some-specific antibodies, followed by 
the appearance of anti-dsDNA and anti-
histone antibodies as a result of epitope 
spreading.1 In systemic lupus erythemato-
sus patients and lupus mice, nucleosomes 
can be found in the circulation, which are 
spilled from apoptotic cells as a result of a 
defective removal of apoptotic cells, due to 
either an enhanced apoptosis or a defec-
tive cleaning machinery.2 Th e nucleosome 
is composed of 146 bp of dsDNA, wrapped 
twice around an octamer of histones (pairs 
of the histones H2A, H2B, H3, and H4), 
and contains both negatively charged 
domains (that is, dsDNA) and positively 
charged domains (that is, histones).
Crossreactivity of anti-dsDNA antibodies 
with glomerular antigens
The indirect evidence for the relation 
between anti-dsDNA antibodies and lupus 
nephritis has fueled experimental work to 
demonstrate more directly the nephri-
togenicity of anti-dsDNA antibodies. As 
lupus nephritis is regarded as a prototype 
of an immune complex-mediated dis-
ease, reconstituted dsDNA/anti-dsDNA 
complexes were injected into animals. 
However, this never led to a glomerular 
localization of these complexes. In con-
trast, injection of anti-dsDNA antibodies 
alone did sometimes lead to glomerular 
localization, which was used as an argu-
ment for the direct nephritogenicity of 
anti-dsDNA antibodies. In the early 1980s, 
seminal papers were published describ-
ing the broad reactivity of lupus-derived 
monoclonal anti-dsDNA antibodies that 
promiscuously recognized a great variety 
of non-related (glomerular) antigens.3
Several studies in mice, in which anti-
dsDNA antibodies were injected or anti-
dsDNA hybridomas were inoculated, 
showed evidence for glomerular bind-
ing of anti-dsDNA antibodies.4 Immu-
noglobulin isolated from serum of lupus 
patients bound to isolated glomeruli. 
This could be inhibited by dsDNA but 
was not abrogated by DNase I treatment 
of the glomeruli.5 Together with the fi nd-
ing that DNase I treatment did not abolish 
the binding of anti-dsDNA antibodies to 
glomerular antigens, this led to the formu-
lation of the hypothesis that sub-popula-
tions of anti-dsDNA antibodies could bind 
directly to intrinsic glomerular antigens, 
such as laminin, heparan sulfate (HS), 
and α-actinin (reviewed by Waldman and 
Madaio4). It appeared that broadly cross-
reactive anti-dsDNA antibodies were the 
most nephritogenic, lending further sup-
port for the crossreactive recognition of 
glomerular antigens. Th e crossreactivity 
of anti-dsDNA antibodies to non-nucleo-
somal antigens was explained to be due 
to (1) the negative charge, as in HS linked 
to proteoglycans; (2) common structures, 
such as phosphodiester groups in phos-
pholipids; and (3) molecular mimicry of 
dsDNA structures, as has been suggested 
for α-actinin.
Pathogenic anti-dsDNA antibodies have 
been reported to react with α-actinin. 
Together with the observation that sera 
of systemic lupus erythematosus patients 
and lupus mice have high titers of anti-
α-actinin antibodies,6 these data seem to 
support the crossreactivity hypothesis. 
But the logical prerequisite for this cross-
reactivity model is that these antigens are 
accessible on the surface of glomerular 
cells or in the glomerular basement mem-
brane (GBM). Th ere is no clear evidence 
that the podocytic protein α-actinin is 
expressed at the cell surface or extracellu-
larly, in contrast to the other crossreactive 
targets. Th ese studies indicate that some, 
but not all, anti-dsDNA antibodies can 
bind to glomerular antigens and to the 
GBM in vitro and in vivo.
Nucleosome-mediated autoantibody 
b in d ing to the glomerular basement 
membrane
It was found that anti-dsDNA antibodies 
and immunoglobulin eluted from kidneys 
from systemic lupus erythematosus mice 
and patients could bind to the negatively 
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charged HS side chain of HS proteogly-
cans.2 It was hypothesized that this reac-
tivity with HS was due to crossreactivity of 
anti-dsDNA antibodies with the anionic 
sites of HS mimicking dsDNA. How-
ever, aft er extensive purifi cation of anti-
dsDNA antibodies, the binding to HS 
was completely lost and could be restored 
only by the addition of histones and 
dsDNA.2 More detailed analysis showed 
subsequently that DNase I treatment of 
complexed antibodies did not remove 
dsDNA completely, whereas histones 
remain bound. More vigorous purifi cation 
methods including DNase I treatment fol-
lowed by stringent high-salt conditions 
were required to remove all nucleosomal 
material.7 Many of the observations on 
crossreactivity were based on the use of 
monoclonal antibodies. Th ese antibodies 
become complexed to nucleosomal mate-
rial released from dying hybridoma cells. 
Th is gives rise to spurious binding proper-
ties, which are not abrogated with DNase 
I treatment.
To evaluate whether binding to HS 
could also occur in vivo, renal perfusion 
studies were performed. Indeed, anti-
nucleosome/anti-dsDNA autoantibod-
ies complexed to nucleosomes bound 
strongly to the GBM, in contrast to 
purifi ed non-complexed autoantibod-
ies. Removal of HS before the perfusion 
of the nucleosome-complexed antibod-
ies prevented glomerular binding.7 Th is 
is supported by an almost complete 
absence of staining for HS in the GBM in 
both human and murine lupus nephri-
tis. Th e disappearance of HS staining is 
due to masking of HS by nucleosome/
immune complexes. Recently, we could 
show that elution of immune complexes 
from renal sections restored the staining 
of HS (unpublished data). Further sup-
port was the ability of heparin to prevent 
the glomerular binding of nucleosome-
complexed autoantibodies and to post-
pone murine lupus nephritis in vivo.2 
Subsequently, we could show in vivo that 
glomerular binding especially occurred 
if nucleosomes were complexed to anti-
dsDNA or anti-nucleosome and not to 
anti-histone antibodies.2 Th e binding of 
anti-nucleosome or anti-dsDNA antibod-
ies to the nucleosome will mask its nega-
tive charge and will facilitate the binding 
of the positively charged N-terminal his-
tone tails to the negatively charged HS in 
the GBM. On the other hand, the binding 
of anti-histone antibodies to the N-termi-
nal histone tails will mask their positive 
charge, preventing deposition of nucleo-
some/immune complexes (Figure 1).
Besides HS, collagen IV has also been 
proposed as a ligand for nucleosome-
mediated binding to the GBM.8 Treatment 
of the GBM with collagenase IV prevented 
binding, which could be restored only 
aft er the addition of collagen IV. It was 
suggested that nucleosomes bind to colla-
gen IV via their histone parts, analogously 
to the situation with HS.8
Kalaaji et al.9 (this issue) provide con-
vincing evidence that nephritogenic 
autoantibodies bind to apoptotic chroma-
tin structures in the GBM. In their previ-
ous study on murine lupus nephritis,10 
they already showed that there was no 
colocalization of in vivo-bound autoan-
tibodies and antibody probes specifi c for 
α-actinin, laminin, or collagen IV. Unfor-
tunately, they did not perform these analy-
ses on the human kidney sections. Th e in 
vivo-bound autoantibodies in the GBM 
colocalized with chromatin identifi ed with 
the TdT-mediated dUTP nick end labeling 
technique.9,10 Although only a limited 
number of renal biopsies were evaluated, 
the impact of their current study9 and their 
previous study10 is considerable. Using 
elegant methods, they accurately defi ne 
the glomerular localization and target 
antigens of anti-dsDNA autoantibodies 
in lupus nephritis. In our opinion, their 
fi ndings should lead to a re-evaluation of 
the crossreactivity hypothesis.
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Figure 1 | Schematic representation of the two hypotheses for the glomerular binding 
of autoantibodies in lupus nephritis. From left to right: direct binding of crossreactive 
autoantibodies to non-nucleosomal glomerular antigens; nucleosome-mediated binding of 
complexed autoantibodies to heparan sulfate (HS). The nucleosome-mediated binding does not 
occur with (1) non-complexed anti-nuclear antibodies or (2) free nucleosomes. Binding of (3) 
anti-dsDNA (blue) or (4) anti-nucleosome antibodies (green) will decrease the density of negative 
charges of the nucleosome. This will enhance binding of the complex to the negatively charged 
HS and lead to nucleosome-mediated binding. In contrast to this, binding of (5) anti-histone 
antibodies (red) to the nucleosome will decrease the amount of positive charges, which reduces 
the capacity to bind to HS in the glomerular basement membrane.
